FTZ can also upregulate the expression levels of P-AMPK and BCL-2 while downregulating BAX, thereby improving steatosis and hepatocyte apoptosis to attenuate NASH [122]. Here, BCL2 is linked to metabolic dysfunction-associated steatohepatitis.